//Your Connection to the Life Sciences Industry
Connect to IBC:LinkedIn iconTwitter iconFacebook iconBlog iconRSS icon
EmailPrint

Find Another IBC Event

Bioconjugates: From Targets to Therapeutics

CSS

Increase Your Market Share with the Latest Conjugation Design and Manufacturing Science

June 04-06, 2014
Grand Hyatt Hotel
San Francisco, CA

Event Overview

Event Overview

Event Wrap-Up

At the Bioconjugates conference held June 4-6, 2014 in San Francisco, attendees heard the latest updates on ADCs, conjugated vaccines, imaging and radiotherapy, as well as other bioconjugates for a comprehensive update on this exploding field. They learned how to design better molecules by learning about novel linkers and payloads from ImmunoGen, MedImmune/Spirogen, Centryrex, Rinat-Pfizer, Genentech and The University of Georgia. Reports demonstrated which technologies are showing the most exciting clinical advances with reports from Seattle Genetics and Genentech. Participants evaluated the most promising site specific conjugation techniques for manufacturability and biological function.

"It was a pleasure presenting at the Bioconjugates conference in June 2014. The presentations and discussion were very stimulating and there was excellent new information." - Philip Howard, Ph.D., Chief Scientific Officer, Spirogen, United Kingdom

The Site Specific Conjugation through Carbohydrates and Alternative Scaffold and Delivery Strategies sessions emphasized the explosive growth and technological progress that's occurred in these areas. In addition to several flavors of antibody-drug and peptide conjugates, next-generation polymers and polymer conjugates were also described. Academic and industry scientists now have a diverse set of tools for producing tailored conjugates for therapeutic and other applications.

The Site Specific Conjugation and Novel Linkers interactive panel discussion brought together key opinion leaders for a vibrant discussion with conference attendees. Although the consensus was that therapeutic benefit of site-specificity remains to be demonstrated, CMC, regulatory and other advantages were delineated. Liabilities with some site-specific schemes were noted and contrasted with alternatives. The panel session closed on a positive note with eager anticipation of the clinical data on next-generation conjugates to be generated over the coming years.

"Great variety of bioconjugation modalities. I'm sure this sort of crosstalk will create new innovations." - Roger Pak, Pfizer

The roundtable discussions in the exhibit hall during lunchtime fostered very lively discussions and networking and it wasn't all work. Attendees got a chance to unwind on Pier 39 along San Francisco Bay for an evening reception at Players Sports Grill, in a bar that resembled a tiki house. At Players' adjacent arcade, we can confirm that several speakers also have Ph.D. credentials in hoops and skee ball.

Plan now to attend next year so you can benchmark your projects and quickly assess the latest technologies to move your projects forward fast!

"A great conference with all the experienced scientists involved in ADC therapeutics - 'one-and-only shop for ADCs' - great location too." - Ananda Senevir, Agensys

BPI 2014